Back

Non-invasive Prenatal MT-RNR1 Pharmacogenetic Testing for the Prevention of Aminoglycoside-Induced Profound Hearing Loss

2026-01-06 genetic and genomic medicine Title + abstract only
View on medRxiv
Show abstract

Irreversible profound hearing loss in early childhood impairs severely the development of spoken language, behavior and cognition. Hearing loss caused by aminoglycoside antibiotics in neonates treated for sepsis in intensive care units is linked to variants in the MT-RNR1 gene. Identifying the population at risk in acute medical settings is substantially limited by genotyping restricted to m.1555A>G only with 20% failure rate of the currently approved point-of-care test. We report an innovative ...

Predicted journal destinations

1
Scientific Reports
701 training papers
Top 5% 17.7%
2
Genetics in Medicine
57 training papers
Top 0.9% 11.8%
3
PLOS ONE
1737 training papers
Top 66% 7.8%
4
The American Journal of Human Genetics
77 training papers
Top 3% 6.4%
5
Genome Medicine
56 training papers
Top 1% 5.9%
6
Nature Communications
483 training papers
Top 26% 4.2%
7
European Journal of Human Genetics
25 training papers
Top 0.4% 4.2%
8
PLOS Genetics
39 training papers
Top 2% 2.8%
9
Human Molecular Genetics
28 training papers
Top 2% 1.9%
10
Genes
21 training papers
Top 0.3% 1.9%
11
Journal of Medical Genetics
22 training papers
Top 0.7% 1.9%
12
International Journal of Molecular Sciences
39 training papers
Top 1% 1.9%
13
Nature Genetics
72 training papers
Top 6% 1.9%
14
Human Genetics and Genomics Advances
39 training papers
Top 3% 1.9%
15
Frontiers in Genetics
32 training papers
Top 1% 1.9%
16
npj Genomic Medicine
18 training papers
Top 0.8% 1.5%
17
Cell Genomics
34 training papers
Top 4% 1.5%
18
BMC Medicine
155 training papers
Top 23% 1.2%
19
The Journal of Molecular Diagnostics
24 training papers
Top 1% 1.2%
20
Cell Reports Medicine
49 training papers
Top 5% 0.9%
21
Nature
58 training papers
Top 10% 0.7%
22
Translational Psychiatry
94 training papers
Top 10% 0.7%
23
Bioinformatics
24 training papers
Top 3% 0.7%